Navigation Links
Genta Incorporated to Present Multiple Abstracts at the Annual,Meeting of the American Society of Clinical Oncology

BERKELEY HEIGHTS, N.J., May 25, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced that several abstracts featuring its oncology products, Genasense(R) (oblimersen sodium) Injection, and Ganite(R) (gallium nitrate injection), will be presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. The abstracts include the following:

    -- LDH is a Prognostic Factor in Stage IV Melanoma Patients but is a

       Predictive Factor only for Bcl-2 Antisense Treatment Efficacy: Re-

       analysis of GM301 and EORTC18951 Randomized Trials.  Abstract #8552;

       Sunday, June 3, 2007.

    -- A Phase III Randomized Trial of Intensive Induction and Consolidation

       Chemotherapy +/- Oblimersen (Genasense; G3139), a Pro-Apoptotic Bcl-2

       Antisense Oligonucleotide, in Untreated Acute Myeloid Leukemia Patients

       greater than or equal to 60 Years Old: Cancer and Leukemia Group B

       (CALGB) Study 10201. Abstract #7012; Saturday, June 2, 2007.

    -- GaRD Study: Gallium, Rituximab, and Dexamethasone for Relapsed NHL.

       Poster #Y1, Abstract #8079; Saturday, June 2, 2007.

    -- Oblimersen (Genasense(R)) Can Be Administered by Subcutaneous and Brief

       Intravenous Infusion: Clinical Pharmacokinetics and Pharmacodynamics in

       Patients with Advanced Cancer. (Publication)

    -- Long-term Administration of Oblimersen plus Chemotherapy: An Analysis

       of Safety in Patients with Solid Tumors and Hematologic Cancers.

       (Publication)

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblim
'"/>




Page: 1 2 3

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:
(Date:11/6/2009)... -- Philips Respironics applauds the efforts of th... to raise awareness about an important public heal... release of the first-ever government study to mon...s a milestone in quantifying the size and scope of...stry leader and sleep therapy manufacturer, Philip...
(Date:11/6/2009).../ -- Cyberonics, Inc. (Nasdaq: CYBX ) today annou...s for the second quarter ended October 23, 2009 of...y, November 18, 2009 at 5:00 PM EST. The company ...sults on Thursday, November 19, 2009 at 9:00 AM ES... Conference Call Instructions ,, To listen to...
(Date:11/6/2009)... , - Trial Will Compare NXL103 With Leadi...-Resistant Staphylococcus Aureus (MRSA) Infections...ompany focused on the discovery and,development of...icant global,problem of microbial resistance, anno...ial NXL103 (flopristin/linopristin), has started a...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 1Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 2Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 3Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 4Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 5Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 6Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 7Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 1DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 2DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 3DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 4DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 5DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 6DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 7DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 9DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 10DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 11DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 12DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 13Rockport Healthcare Group Continues to Grow Coverage Area With New Work Comp Network Certification in Georgia 54149 1Rockport Healthcare Group Continues to Grow Coverage Area With New Work Comp Network Certification in Georgia 54149 2
...e many, clinical studies are few, NEW YORK, Aug. ...that a limited amount of clinical research exists,...r (OTC) anti-aging,products. The study is publishe...urgery Journal, the official peer-reviewed journal...gery (ASAPS). OTC anti-aging products represent a...
...tional Stem,Cell Holding, Inc. (OTC: NHGI.PK), tod...y, and Jacob Cohen, have discovered biomaterial de...s to promote tissue repair in,various wound care a...ced that while using its,proprietary embryonic ste...,group of biomaterials that in preclinical studies...
Other Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 3
(Date:11/7/2009)...d for Life Action endorses a key vote today on the...Dahlkemper-Lipinski-Smith Amendment, an Amendment ...on in health care reform. ,, Americans United for ...t said, "Americans United for Life Action strongly...mper-Lipinski-Smith Amendment to prohibit abortion...
(Date:11/7/2009)...uth will rebel, expert says , , SATURDAY, ...o behave badly if their parents expect them to, a ...hey are simply being realistic might actually cont...hanan, a psychology professor at Wake Forest Unive...sity news release. "Negative expectations on the p...
(Date:11/7/2009)...-25th marked the 12th annual tournament bringing t...e against pediatric cancer. Stephen Updegraff, MD...r many years. , St. Peter...d of October 23-25 marked the 12th annual tournam...ting the battle against pediatric cancer– To...
(Date:11/7/2009)...quo;sweatox’ or ‘Boytox’, the ne...i-ageing jab ‘Breastox’ – or bre...colletage, can reduce the appearance of wrinkles a...sts, leaving smoother, younger-looking skin. , ...Transform, the UK’s largest group of cosmet...
(Date:11/6/2009)...ER, Nov. 6 /PRNewswire-FirstCall/ - Cardiome Pharm...d that it will report financial results for the th...g of Monday, November 9, 2009. Cardiome will hold ...n (6:00am Pacific) on that day to discuss the resu... 416-695-7806 or 888-789-9572 and reference confer...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3Health News:UK Boobs Get a Boost with 'Breastox' 2Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3
...A new study has found that single tablets containi...olling increasing blood pressure in people with e...al study named ACCOMPLISH (Avoiding Cardiovascular...niversity of Michigan Medical School. As p...
...Stanford University School of Medicine researchers...of the body's immune system known as troublemaker...ficial for metabolism. The new finding is ...eputation for being the bad guys. We have found th...
...The lives of laborers begin from mines and end wit...desh. Forced to work in illegal stone quarries b...o silica dust puts the laborers at high risk of ge...villages of Madhya Pradesh's Morena district. ...
...A new study has found that apart from using mobile...f passengers in a vehicle could increase the risk...itute for International Health, was intended to de...und that passengers also contribute to road accide...
...Addressing the concerns of developing countries li...World Health Organization (WHO), has promised eff...istribution of pandemic influenza vaccines at affo... A resolution on those lines is being adopted by t...
...One almost freezes in horror watching the ghastly ...ocks, on the ground then, covering her head as sto...shed with a concrete block, blood oozes from her h...ad, 17, was to love a boy from another religion. S...
Other Medicine News:Health News:Single-tablet With Two Drugs may Help Control High BP Better 2Health News:Macrophages may Help Prevent Obesity 2Health News:Miners in Madhya Pradesh at High Risk of Developing TB 2Health News:Not Only Mobile Phones, Even Passengers can Increase the Risk of Road Accidents 2Health News:WHO Announces Deal on Sharing Bird Flu Virus 2Health News:Women in Iraq More Unsafe Than Ever 2
Arrow QuadPolar EP Catheter
Mayfield Triad Skull Clamp
...umin Strips provide albumin, creatinine and albumi...linitek Microalbumin product is useful to test for...ertension in order to detect early kidney disease....f the urinary albumin excretion rate, is an indica...
Clinitek Atlas Automated Urine Chemistry Analyzer (Rack)
Medicine Products: